Tag Archive for: ADC

Synaffix Announces Expansion of ADC Collaboration with MacroGenics

/in

MacroGenics adds up to four ADC programs MacroGenics may combine both its proprietary antibody and bispecific DART® technologies with Synaffix’s linker-payload technologies Expanded collaboration includes up to $2.2 billion in total potential payments plus tiered royalties on net sales  AMSTERDAM, NETHERLANDS, 14 March 2023, Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform […]

Read more

Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs

/in

AMSTERDAM, THE NETHERLANDS, 5 January 2023 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), today announced the signing of a licensing agreement with Amgen to develop next generation ADCs. Amgen will gain access to Synaffix’s antibody conjugation technology platforms comprising GlycoConnect™, HydraSpace™ and select […]

Read more

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

/in

Amsterdam and San Francisco / Houston / Singapore, 4 January 2023 — Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Hummingbird Bioscience (Hummingbird Bio), a data-driven precision biotherapeutics company using its Rational Antibody Discovery (RAD) platform to discover and […]

Read more

Another Award for Synaffix: ‘Business Development Team of Year’ at the Scrip Awards

/in

AMSTERDAM, THE NETHERLANDS, December 13, 2022 – Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that the Company has been awarded ‘Business Development Team of Year’ at the annual Scrip Awards ceremony held on the 30th of November, at […]

Read more

Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards

/in

AMSTERDAM, THE NETHERLANDS, November 16, 2022 – Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of November at […]

Read more